Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans

BACKGROUND:Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein B100 (apoB). Although studies in mice and cells have identified increased hepatic LDL receptors as the basis for LDL lower...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 2017-01, Vol.135 (4), p.352-362
Hauptverfasser:	Reyes-Soffer, Gissette, Pavlyha, Marianna, Ngai, Colleen, Thomas, Tiffany, Holleran, Stephen, Ramakrishnan, Rajasekhar, Karmally, Wahida, Nandakumar, Renu, Fontanez, Nelson, Obunike, Joseph, Marcovina, Santica M, Lichtenstein, Alice H, Matthan, Nirupa R, Matta, James, Maroccia, Magali, Becue, Frederic, Poitiers, Franck, Swanson, Brian, Cowan, Lisa, Sasiela, William J, Surks, Howard K, Ginsberg, Henry N
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antibodies, Monoclonal - administration & dosage Female Healthy Volunteers Humans Lipoproteins, VLDL - metabolism Male Middle Aged Original s Proprotein Convertase 9 - antagonists & inhibitors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!